Premium
Clonazepam quantification in human plasma by high‐performance liquid chromatography coupled with electrospray tandem mass spectrometry in a bioequivalence study
Author(s) -
Cavedal Luiz E.,
Mendes Fabiana D.,
Domingues Claudia C.,
Patni Anil K.,
Monif Tausif,
Reyar Simrit,
Pereira Alberto dos S.,
Mendes Gustavo D.,
De Nucci Gilberto
Publication year - 2007
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/jms.1141
Subject(s) - chemistry , chromatography , bioequivalence , electrospray , tandem mass spectrometry , mass spectrometry , liquid chromatography–mass spectrometry , clonazepam , high performance liquid chromatography , human plasma , pharmacokinetics , pharmacology , medicine
A rapid, sensitive and specific method for quantifying clonazepam in human plasma using diazepam as the internal standard (IS) is described. The analyte and the IS were extracted from plasma by liquid‐liquid extraction using a hexane/diethylether (20 : 80, v/v) solution. The extracts were analysed by high‐performance liquid chromatography coupled with electrospray tandem mass spectrometry (HPLC‐MS‐MS). Chromatography was performed on a Jones Genesis C8 4 µm analytical column (100 × 2.1 mm i.d.). The method had a chromatographic run time of 3.0 min and a linear calibration curve over the range 0.5–50 ng/ml ( r2 > 0.9965). The limit of quantification was 0.5 ng/ml. This HPLC/MS/MS procedure was used to assess the bioequivalence of two clonazepam 2 mg tablet formulations (clonazepam test formulation from Ranbaxy Laboratories Ltd and Rivotril from Roche Laboratórios Ltda as standard reference formulation). Copyright © 2006 John Wiley & Sons, Ltd.